Tuesday, January 17, 2017 1:15:36 PM
PR Newswire
BAUDETTE, Minn., Jan. 17, 2017
BAUDETTE, Minn., Jan. 17, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs, effective January 17, 2017.
Karen Quinn is a professional with over 30 years of leadership experience in Global Regulatory Affairs, specifically with a focus on drug products with biologically-derived active pharmaceutical ingredients. Dr. Quinn worked most recently with Takeda Pharmaceuticals International as Senior Director, Global Regulatory Affairs/CMC and Head of the Biologics Group. Dr. Quinn has also held various global regulatory affairs positions with The Dow Chemical Company, Proctor & Gamble Pharmaceuticals, Solvay Pharmaceuticals, Wyeth Pharmaceuticals and Millennium Pharmaceuticals.
Arthur S. Przybyl, ANI's President and Chief Executive Officer, stated, "I am pleased that Karen has joined ANI to help lead the advancement of our most exciting pipeline opportunity, which is the re-commercialization of our Corticotrophin NDAs. ANI intends to continue to expand resources devoted to this project as we enter what is going to be a very important year for development of our Corticotropin products."
Mark Ginski, ANI's Vice President of Corticotropin Product Development, stated, "I am confident that Karen's highly relevant regulatory affairs experience will bring valuable insight to the Corticotropin project. More specifically, Karen has led regulatory efforts that resulted in the successful FDA approval for an older biologically-derived drug product when it was demonstrated that it met updated FDA requirements for effectiveness, safety and manufacturing consistency."
Recent ANIP News
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 04/18/2024 08:05:00 PM
- ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension • GlobeNewswire Inc. • 04/09/2024 10:50:00 AM
- ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis • GlobeNewswire Inc. • 04/04/2024 10:50:00 AM
- ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium • GlobeNewswire Inc. • 04/03/2024 10:50:00 AM
- ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP • GlobeNewswire Inc. • 03/27/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:25:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:59:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:26:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:42:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:21:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:16:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:11:59 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:58:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:31:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 09:29:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:24:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 10:00:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 12:18:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:18:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:09:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:06:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:03:56 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM